by guest www.bloodjournal.org From 2 KEY POINTS 1. Mice lacking mast cells have severely exacerbated GVHD as compared to WT controls. 2. Engraftment of mast cells into mast-cell deficient animals improves survival, but not if the mast cells are derived from IL-10 KO mice.
INTRODUCTION
Traditionally, mast cells are best known as promoters of immunity and inflammation in response to pathogens as well as in allergic disorders 1 . However, there are other settings where mast cells appear to play an immunomodulatory role and suppress immune reactions. Mast cell precursors originate from hematopoietic stem cells and reside in vascularized tissue or serosal cavities, especially in surfaces which interact with the environment such as the gastrointestinal tract, airways, and skin [2] [3] [4] . There they mature and can persist for long periods of time [2] [3] [4] .
There are several studies implicating mast cells in graft-versus-host disease (GVHD) pathogenesis. It has been noted that in connective tissue, particularly in the skin, mast cells disappear during chronic GVHD 5, 6 ; however, it was later demonstrated that the "disappearance" was merely a loss of toluidine blue staining of mast cell granules and that the mast cells remained. 7 The conclusions of these studies were that mast cells were degranulating after activation, presumably by alloreactive donor T cells, resulting in the stimulation of fibroblasts, collagen secretion, and dermal fibrosis. 7 Murphy et al. 8 demonstrated that in a CD8 + T cellmediated model of GVHD, C57BL/6-Kit W/Wv recipients, that lack mast cells, had prolonged survival over WT B6 recipients. Furthermore, they suggested that the degranulation of mast cells resulted in early epithelial injury. Another study used peptide antagonists for the IgE/FcεRI receptor interaction, which triggers activation of mast cells and other cell types after they are cross-linked by antigen 9 . These peptides significantly inhibited GVHD development, again implicating mast cells as a driver of pathology in at least some models of GVHD.
In recent years, several studies have revealed that mast cells are much more functionally diverse than previously thought, and can have potent immunoregulatory roles. 1 In particular, Lu et al. 10 demonstrated that administration of anti-CD154 antibody together with an intravenous infusion of allogeneic cells (donor-specific transfusion; DST) induced acceptance of skin allografts in wild-type (WT) but not in C57BL/6-Kit W-sh/W-sh mice (which virtually lack mast cells). Furthermore, engraftment of mast cells in the skin extended graft survival in C57BL/6-Kit W-sh/Wsh mice, which previously could not sustain allografts. Based on the increased presence of both mast cells and Tregs in tolerated skin grafts, together with the production of IL-9 (a mast cell growth and activation factor) by Tregs, Lu et al. proposed a functional role for mast cells as intermediaries in regulatory T cell-induced tolerance. In light of these findings in a model of allogeneic skin graft tolerance in C57BL/6-Kit W-sh/W-sh mice, we re-examined the role of mast cells in GVHD in C57BL/6-Kit W-sh/W-sh mice and investigated whether Treg suppression of GVHD may involve mast cells. Our results provide evidence for an anti-inflammatory and immunoregulatory role for mast cells in GVHD.
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Methods

Mice
Experiments used gender-matched mice between 7-16 weeks old. FVB (H-2 q ), BALB/c(H-2 d ), C57BL/6(H-2 b , CD45.2), and B6(Cg)-Tyrc-2J/J(H-2 b , CD45.2) and IL-10 -/-(B6.129P2-Il10tm1Cgn/J) were purchased from Jackson Laboratories (Sacramento, CA) and acclimated to the Stanford animal facility for a minimum of 3 days before every experiment. Genetically mast cell-deficient mice C57BL/6-Kit W-sh/W-sh and C57BL/6-Cpa3-Cre; Mcl-1 fl/fl mice (which had been back-crossed to C57BL/6J mice for over 10 generations) are as described and maintained in the Stanford animal facility. 11, 12 Luciferase-expressing (luc + ) FVB/N L2G85 and C57BL/6 mice were generated as described and raised in the Stanford animal facility. 13, 14 Animal protocols were approved by the Institutional Animal Care and Use Committee of Stanford University.
Cell isolation
CD4/CD8 conventional T cells (Tcon) were prepared from splenocytes and peripheral lymph node cells, and enriched with anti-CD4 MACS (Miltenyi Biotec, Auburn, CA) (Miltenyi Biotec, Auburn, CA), then anti-CD8 MACS; purity was assessed by FACS on a LSR II or FACS Aria (BD Biosciences, San Jose, California) and cells were mixed so CD4:CD8 = 2:1. T-cell depleted bone marrow (TCD-BM) was prepared by flushing bones and depleting T cells with anti-CD4 and anti-CD8 MACS beads. Treg were prepared from pooled spleens and lymph nodes, by staining for CD25-APC and CD4, enriching with anti-APC MACS, and sorting for CD4 + CD25 hi cells on a FACS Aria or FACS Aria II (BD Biosciences).
Flow cytometric analysis
The following antibodies were purchased from BD Pharmingen (San Diego, CA), eBioscience (San Diego, CA), and Biolegend (San Diego, CA): CD4 (GK1.5), CD8 (53-6.7), CD25 (PC61), FcεR1α (MAR-1), CD117 (2B8), and Foxp3 (FJK-16s). Foxp3 staining was performed with antimouse/rat Foxp3 Staining Set (eBiosciences). To stain dead cells, propidium iodide was used for freshly-isolated cells and Ethidium Monoazide (EMA) (Molecular Probes, Carlsbad, CA) for fixed cells. Analysis was performed on a FACS Aria or LSRII (Becton-Dickinson, CA).
Preparation and engraftment of BMCMCs
BMCMCs were obtained by culture of bone marrow cells from femurs and tibia from either WT, luc + , or IL10 -/-C57BL/6 mice and cultured for 4-6 weeks in 20% (vol/vol) medium conditioned by the growth of the WEHI-3 mouse myelomonocitic cell line (containing IL-3); at this time, over 95% of the cells were identified as mast cells by flow cytometry (FcεRI + , c-Kit + ). For mast cell-engraftment studies, 5x10 6 BMCMCs were injected i.p. into C57BL/6-Kit W-sh/W-sh pups 4-5 weeks or age, and experiments were initiated 6-8 weeks later.
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From Transplantation model to evaluate GVHD C57BL/6-Tyr c-2J /J or C57BL/6-Kit W-sh/W-sh recipients were treated with total body irradiation (TBI) (200 Kv X-ray source), consisting of 2 doses of 5 Gy, 4 hours apart. 5x10 6 TCD-BM (C57BL/6) were injected via tail vein on day 0, followed by WT or luc + Tcon (C57BL/6) to induce GVHD. Transplanted animals were kept in autoclaved cages with antibiotic water (sulfamethoxazole-trimethropim; Schein Pharmaceutical, Corona, CA).
In vivo and ex vivo bioluminescence imaging
Bioluminescence imaging was performed as described 15 with an IVIS 7, IVIS 29, or IVIS Spectrum charge-coupled device (CCD) imaging system (Xenogen, Alameda, CA). Images were analyzed with Living Image Software 2.5 (Xenogen) and Igor Pro Carbon (Wavemetrics, Lake Oswego, OR). 
Mixed Lymphocyte Reaction
Histology and quantification of mast cells
Mice were euthanized and tissues were fixed in 10% (vol/vol) buffered formalin and embedded in paraffin, and sections 4 mm in thickness were cut. Mesenteric windows were arranged onto slides and fixed for 1 hour in Carnoy's solution (3:2:1 v/v/v of ethanol, chloroform, and acetic acid). All tissues were stained with Csaba stain for mast cell detection. Mast cells were quantified according to area (mm 2 ) or expressed in numbers per mm horizontal field length using computer-generated image analysis (NIH Image J software,version 1.29)
Statistical analysis
Differences in animal survival (Kaplan-Meier survival curves) were analyzed by log-rank test. All other comparisons were performed with the 2-tailed Student t test and a P value of less than .05 was considered statistically significant.
RESULTS
GVHD is exacerbated and T cell survival/proliferation is increased in C57BL/6-Kit W-sh/W-sh mice
Because mast cell-deficient mice were reported to more readily reject skin grafts 10 , we hypothesized that host mast cells also may play an anti-inflammatory or immunoreglatory role in GVHD. We employed a major-mismatch model of acute GVHD in which T-cell depleted bone marrow cells (TCD-BM) and 2x10 6 MACS-enriched CD4/CD8 conventional T cells (Tcon) from FVB mice (H-2 q ) were transferred into allogeneic C57BL/6 recipients (H-2 b ) which had received myeloablative irradiation. To assess the influence of mast cells in disease induction, C57BL/6-Kit W-sh/W-sh recipients (which virtually lack mast cells) were also used as recipients. We observed a severe exacerbation of GVHD and more rapid death in C57BL/6-Kit W-sh/W-sh recipients, with a median survival time (MST) of 13 days as compared to a MST of 60 days in C57BL/6 WT recipients ( Figure 1, p<0 .0001). The difference in survival was most pronounced when Tcon were administered 4 days after transplantation (shown), but also was observed if Tcon were administered on Days 0, 2, or 7 of transplantation (Day 2, Figure 3c ; others not shown).
To confirm that the differences in survival observed between C57BL/6-Kit W-sh/W-sh recipients and wild-type mice were due to a lack of mast cells and not any other strain-specific factor, we repeated our GVHD survival study in a new mast cell-deficient model mouse, C57BL/6-Cpa3-Cre;Mcl-1 fl/fl (Supplemental Figure 1 ). These mice have normal expression of c-Kit, but have a severe deficiency in mast cells (92-100%) and a marked deficiency in basophils (58-78%). 12 In agreement with what was observed with C57BL/6-Kit W-sh/W-sh recipients, there was an exacerbation of GVHD and more rapid death in C57BL/6-Cpa3-Cre;Mcl-1 fl/fl recipients, with an MST of 8 days as compared to an MST of 77 days in C57BL/6 WT recipients (Supp. Figure 1 , p<0.0001).
The exacerbation of GVHD in mast cell-deficient recipients suggested that mast cells might be exerting an immunosuppressive effect on Tcon survival and/or proliferation during GVHD induction. To explore this possibility, we utilized luciferase positive (luc + ) Tcon where T cell populations can be assessed in vivo with bioluminescence imaging (BLI) 16 . Utilizing BLI, which has been validated as a tool for assessing cell survival/proliferation, we observed significantly increased numbers of T cells in mast cell-deficient C57BL/6-Kit W-sh/W-sh mice as compared to WT recipients (Figure 2 , P<0.01). The differences in donor-derived T cell survival/proliferation were most pronounced in total photons emitted from gut (2 fold), liver (2.7 fold), and lymph nodes (3.3 fold).
Mast cell-deficient C57BL/6-Kit W-sh/W-sh mice have normal numbers and function of CD4 + CD25 + Treg
Based on the increased presence of both mast cells and Treg in tolerated skin grafts, together with the production of IL-9 (a mast cell growth and activation factor) by Treg, Lu et al. 10 proposed a functional role for mast cells as intermediaries in regulatory T cell-induced tolerance. Furthermore, since C57BL/6-Kit W-sh/W-sh mice exhibited increased Tcon numbers and, consequently exacerbated GVHD, we investigated whether these mast cell-deficient mice may have a Treg deficiency or if Treg isolated from such mast cell-deficient mice were less effective in suppressing T cell proliferation. We observed similar numbers and percentages of FoxP3 + CD4 cells in both C57BL/6-Kit W-sh/W-sh mice as in corresponding mast cell-containing WT mice in liver, spleen, and lymph node tissues, except for slightly more FoxP3 + cells in the spleen of C57BL/6-Kit W-sh/W-sh mice, probably reflecting the larger size of the spleen in C57BL/6-Kit W-sh/Wsh versus WT mice (Figure 3a ). Furthermore, purified Treg (CD4 + CD25 hi ) from C57BL/6-Kit Wsh/W-sh mice (FoxP3 + expressing cells > 98%) were equally as effective as Treg from corresponding mast cell-containing control mice in exerting significant suppression of Tcon proliferation in vitro in a mixed-leukocyte reaction (Figure 3b ; P<0.05). Therefore, we found no indication that a deficiency in mast cells in C57BL/6-Kit W-sh/W-sh mice results in either a decrease in numbers or function of Treg.
We know from previous studies that Treg can effectively reduce the morbidity and mortality of GVHD in our transplant model [17] [18] [19] . To further investigate a possible Treg-mast cell interaction, we induced GVHD in C57BL/6-Kit W-sh/W-sh mice and in the corresponding mast cell-containing control WT mice and determined if Treg would be as suppressive of GVHD in the absence of mast cells. Using Treg purified from WT FVB donor mice, we observed that the addition of Treg resulted in improved survival and a reduction in GVHD (Figure 3c ). Adoptive transfer of Treg into WT mice receiving Tcon improved the MST to 65.5 days versus a MST of 14 days in mice receiving Tcon only (p<0.02). Similarly, transfer of Treg into C57BL/6-Kit W-sh/W-sh mice improved the survival to a MST of 34 days versus a MST of 10 days in C57BL/6-Kit W-sh/W-sh mice which received Tcon only (p<.001). When we take into account the exacerbation of GVHD induced by Tcon in C57BL/6-Kit W-sh/W-sh recipients, the improvement in survival was even more pronounced when Treg were added to C57BL/6-Kit W-sh/W-sh recipients than to WT recipients. This indicates that, contrary to the hypothesis put forth by Lu et al. 10 based on their studies of skin grafts, we do not find any evidence that Treg function depends on or involves mast cells in our model of GVHD.
Engraftment of mast cells into C57BL/6-Kit W-sh/W-sh mice improves survival in GVHD in a mechanism dependent on IL-10 production by the mast cells.
Although GVHD is worsened in C57BL/6-Kit W-sh/W-sh mice, indicating a potential role for mast cells, these data could also be due to other consequences of the large gene inversion in these mice. We therefore determined whether the impaired survival during GVHD observed in For personal use only. on July 14, 2017. by guest www.bloodjournal.org From C57BL/6-Kit W-sh/W-sh mice might be improved when mast cells were selectively engrafted into these mice. We prepared bone marrow-derived cultured mast cells (BMCMCs) by in vitro incubation of bone marrow in the presence of IL-3. Because mast cell engraftment efficiency in various organs depends on the route of administration 11 , we chose to engraft the mast cells in the peritoneal cavity as gut injury is a major cause of lethality in acute GVHD. BMCMCs were prepared from luc + C57BL/6 WT mice to allow for visualization of effective engraftment of mast cells in vivo in the peritoneal cavity and gut 8 weeks after adoptive transfer (Figure 4a ). Furthermore, since IL-10 production contributed to mast-cell mediated suppression of inflammation in mast cell-engrafted mast cell-deficient mice in models of severe contact dermatitis and UV-induced skin pathology 20 , we hypothesized that IL-10 production by mast cells also might play a critical role in suppression of GVHD. Therefore, we confirmed that BMCMC from C57BL/6-IL-10 -/mice would also engraft into C57BL/6-Kit W-sh/W-sh recipients (Figure 4b ). We observed similar levels of engraftment of BMCMCs derived from WT or IL10 -/donors in the mesenteric window, forestomach, and in the peritoneal cavity (as assessed by examining cells obtained by peritoneal lavage).
Wild type or IL-10 deficient BMCMCs were introduced i.p. into C57BL/6-Kit W-sh/W-sh mice 8 weeks prior to transplantation. The median survival of transplanted animals was significantly improved from 13 days in mast cell-deficient C57BL/6-Kit W-sh/W-sh recipients to 51 days in C57BL/6-Kit W-sh/W-sh mice which had received WT BMCMCs ( Figure 5 ; P<0.01). However, if the engrafted BMCMCs were derived from IL-10 -/mice, the median survival was unchanged at 12 days and thus no significant improvement in survival was observed. Together, these results support the conclusion that a mast cell deficiency contributes to, or possibly even fully accounts for, the exacerbation in GVHD in C57BL/6-Kit W-sh/W-sh recipient mice, and that IL-10 production by mast cells is involved in the mechanism by which mast cells modulate the immune response in this setting.
Discussion
This study provides evidence that mast cells can play an immunoregulatory role in GVHD. When mice were given allogeneic T cells, a dramatic increase in GVHD-associated mortality was observed in mast cell-deficient C57BL/6-Kit W-sh/W-sh and C57BL/6-Cpa3-Cre;Mcl-1 fl/fl mice as compared to WT C57BL/6-Kit +/+ controls. This is in contrast to previous findings using a CD8 only GVHD model where another mast cell-deficient mouse strain (WBB6F 1 -Kit W/W-v ) demonstrated improved survival in the absence of mast cells 8 . However, in the study by Murphy et al., GVHD induction was significantly weaker and survival improvement was slight. Also, the strain combinations used in the two studies may have influenced the finding that WBB6F 1 -Kit W/W-v mice behaved differently than C57BL/6-Kit W-sh/W-sh mice.
Since mast cells have been shown to have an important role in the protection against infection, 21 we cannot dismiss the possibility that the increased mortality observed in mast cell deficient recipients which received allogeneic T cells could be partly due to an increased susceptibility to infection. However, the risk of infection was mitigated in all transplants by the continuous administration of antibiotic in the drinking water of the mice. Also, as our major-mismatch model of GVHD involves significant inflammation and proliferation of T cells, we do not believe that these mice are significantly susceptible to infection as compared to the WT animals. Furthermore, we have demonstrated the novel finding that mast cells in fact are playing an immunoregulatory role in GVHD. The decrease in survival we observed in our model was associated with increased Tcon survival/proliferation in mice lacking mast cells. This finding indicates that the presence of mast cells resulted in a reduction in T cell numbers. As the report by Lu et al. 10 indicated that mast cells can functionally interact with CD4 + CD25 + Treg, we hypothesized that perhaps the C57BL/6-Kit W-sh/W-sh mice might have a deficiency or defect in Treg, yet we found no evidence to support this hypothesis.
Since mast cell production of IL-10 was found to be an important mediator of mast-cell mediated suppression of inflammation in models of severe contact dermatitis or chronic UV irradiation 20 , we investigated whether mast-cell derived IL-10 may be involved in the suppression of GVHD by mast cells. By employing a mast cell engraftment model where bone marrow-derived cultured mast cells from either WT or IL-10 -/deficient donor mice were engrafted pretransplant, we found that adoptive transfer of mast cells into mast cell-deficient animals prolonged survival and that IL-10 production by the mast cells contributed to reducing GVHD and improving survival. It remains to be investigated what may be triggering mast cells to produce IL-10 following the myeloablative conditioning of recipient mice and induction of GVHD. One possibility is lipopolysaccharide (LPS), which accumulates in the bloodstream during GVHD following gut injury. 22, 23 Masuda et al. 24 demonstrated that LPS increased production of Th2-associated cytokines by mast cells, including IL-10. Thus, one hypothesis is For personal use only. on July 14, 2017. by guest www.bloodjournal.org From that LPS released during gastrointestinal injury in GVHD is activating the TLR-4 receptors of mast cells, which in turn produce IL-10 and reduce T cell proliferation.
In conclusion, our data provide evidence that further expands the roles of mast cells in inflammatory diseases and adds a novel immunoregulatory role to the complex repertoire of mast cell functions. As gastrointestinal injury is the likely culprit in the rapid mortality observed in mast cell-deficient C57BL/6-Kit W-sh/W-sh mice, we do not feel that our results necessarily conflict with previous findings that mast cells can contribute to dermal fibrosis in other settings. 7 It is therefore possible that mast cells can play both an inflammatory role in chronic GVHD associated with dermal fibrosis, and an anti-inflammatory role in mucosal tissues and in systemic allogeneic T cell proliferation. Mast cell function in GVHD appears to be dependent on the tissue they reside in and the factors and conditioning to which they are exposed. As a result, further investigation into modulation of mast cell function, and devising approaches to induce mast cells to exhibit enhanced production of IL-10, may lead to improved treatment of GVHD as well as other inflammatory conditions.
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